HealthMore in Health→
Novartis' Pelacarsen Fails Pivotal Cardiovascular Study
Key Takeaways
- Novartis confirmed Friday that pelacarsen did not succeed in a pivotal cardiovascular trial.
- The drug had been closely watched as part of broader efforts to address residual cardiovascular risk.
- The failure represents a significant setback for the company and the therapy area.
- Detailed study findings have not yet been released, and next steps are unclear.
DE
DT Editorial Team··via statnews.com